Novel Parkinson’s Therapy Moves Ahead Through Korea Deal
This article was originally published in PharmAsia News
South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials in the country and is expected to be a first-in-class drug that can curb dopaminergic neuronal cell death.
Register for our free email digests: